Despite research suggesting that there may be increased cardiovascular risk from off-label prescription testosterone use, usage in men with coronary artery disease remains higher than in men without coronary artery disease.
Considerable increase seen from 1997 through 2016, especially in direct-to-consumer advertising
Hypogonadism and serum testosterone evaluation nearly doubled the odds a man would undergo varicocelectomy.
More than half of UK specialists surveyed said measuring testosterone levels in patients with nonmetastatic prostate cancer was not their routine practice.
In a study, the rate of deep vein thrombosis in treated hypogonadal men was just 0.8% over 2 years of follow-up.
Prior to starting Xyosted, the patient’s baseline cardiovascular risk should be considered and blood pressure should be adequately controlled.
Meta-analysis suggests that testosterone treatment enhances mood in hypogonadal and eugonadal men.
In a study, older men with difficulty walking or climbing stairs reported better physical function after testosterone therapy.
Single-dose disposable auto injector approved for once-weekly subcutaneous administration of testosterone may cut down on potential problems associated with other options.
In a recent meta-analysis, testosterone therapy was not associated with major or minor adverse cardiovascular events.